These results suggest that currently hypothesized mechanisms of memantine and ketamine action should be reconsidered and that NR1/2C and/or NR1/2D receptors play a more important role in cortical physiology and pathology than previously appreciated.
, properties of fundamental physiological and pathological importance. Channel block by Mg 2ϩ o reduces Ca 2ϩ influx at membrane voltages near rest, but is relieved during neuronal excitation (Dingledine et al., 1999) . Ca 2ϩ influx through NMDARs induced by synaptic activity is required for many types of synaptic plasticity, and underlies some forms of learning and memory. Excessive Ca 2ϩ influx may result in excitotoxic cell death, one of many NMDAR-mediated processes hypothesized to play a role in neurodegenerative and neuropsychiatric disorders (Dingledine et al., 1999; Krystal et al., 2003; Moghaddam and Jackson, 2003) .
Functional NMDARs are composed of 4 subunits and usually contain NR1 and one or more of the four NR2 (NR2A-NR2D) subunits (Dingledine et al., 1999) . NR2 subunit expression is developmentally and regionally regulated (Monyer et al., 1994; Cull-Candy and Leszkiewicz, 2004) . The identity of the NR2 subunit(s) in an NMDAR strongly influences receptor properties, including agonist affinity, deactivation kinetics, single-channel conductance, Ca 2ϩ permeability, and channel block by Mg 2ϩ o (Dingledine et al., 1999; Cull-Candy and Leszkiewicz, 2004) . Of particular relevance here, NMDAR inhibition by Mg 2ϩ o is considerably weaker in NR1/2C and NR1/2D receptors than in NR1/2A or NR1/2B receptors (Kutsuwada et al., 1992; Monyer et al., 1994; Kuner and Schoepfer, 1996) .
Several drugs of clinical importance, including memantine, act by binding in the channel of NMDARs at a site that overlaps with the Mg 2ϩ o blocking site (Kashiwagi et al., 2002; Chen and Lipton, 2005 ) (see Fig. 1 A) . Memantine block exhibits voltage dependence; the concentration of memantine that inhibits NMDAR responses by 50% (the IC 50 ) increases with depolarization (Rogawski and Wenk, 2003; Johnson and Kotermanski, 2006; Parsons et al., 2007) . Memantine slows the cognitive decline associated with Alzheimer's disease and represents a departure in Alzheimer's disease therapy from previously developed medications that enhance cholinergic transmission (Schmitt, 2005; Lipton, 2006) . Considerable evidence indicates that the therapeutic effects of memantine derive predominantly from NMDAR inhibition (Rogawski and Wenk, 2003; Schmitt, 2005; Lipton, 2006; Parsons et al., 2007) . However, it appears paradoxical that inhibition of NMDARs slows memory loss associated with Alzheimer's disease, since NMDAR activation is essential for memory formation (Dingledine et al., 1999) . Hypotheses proposed to explain the therapeutic actions of memantine include slowing of neuronal loss due to excitotoxic overactivation of NMDARs and correction of an excitation-inhibition imbalance (Rogawski and Wenk, 2003; Schmitt, 2005; Johnson and Kotermanski, 2006; Lipton, 2006; Parsons et al., 2007) . Here, we investigate the possibility that physiological Mg 2ϩ o modifies the inhib-itory properties of NMDAR channel blockers, conferring on them properties that may help explain the clinical utility of memantine.
Materials and Methods
Cell culture and transfection. Experiments were performed on the HEK293T mammalian cell line. Cells were transfected using Lipofectamine (Invitrogen) (Qian and Johnson, 2006) , with cDNA for the NR1-1a [GenBank accession number (ACCN) X63255, in pcDM8] subunit and either the NR2A (ACCN M91561, in pcDM8), NR2B (ACCN M91562, in pcDNA1), NR2C (ACCN M91563, in pcDNA1), or NR2D (ACCN L31612, in pcDM8) subunit. Enhanced green fluorescent protein (eGFP) cDNA was cotransfected as a marker of successful transfection.
Electrophysiology. Whole-cell patch-clamp recordings were performed with an Axopatch-1D amplifier ϳ24 h after transfection. For experiments in 1 mM Mg 2ϩ o , cells with bright eGFP fluorescence (associated with larger NMDAR responses) were chosen. Recording electrodes of 2-6 M⍀ resistance were filled with an internal solution consisting of the following (in mM): 125 CsCl, 10 BAPTA, and 10 HEPES; pH adjusted to 7.20 Ϯ 0.05 with CsOH; osmolality 275 Ϯ 10 mmol/kg. Series resistance was compensated 80 -95%.
External solutions consisted of the following (in mM): 140 NaCl, 2.8 KCl, 1 CaCl 2 , and 10 HEPES (and 1 MgCl 2 when indicated); pH adjusted to 7.20 Ϯ 0.05 with NaOH; osmolality adjusted to 290 Ϯ 10 mmol/kg with sucrose. Solutions were applied to cells by a seven-barrel fast perfusion system. NMDARs were activated by 1 mM glutamate and 100 M glycine. Correction for the Ϫ6 mV junction potential was applied to all data.
Data analysis. Data were low-pass filtered at 100 Hz and analyzed using Clampfit 9.2 (Axon Instruments). Currents averaged during 500 ms time windows were used for all baseline current and steady-state NMDARmediated current measurements. Concentration-inhibition curves were fit using the following equation: 
Results
Identification of an inhibitory drug's site(s) of action requires knowledge of its IC 50 at potential targets under physiological conditions. The median value of many published measurements of memantine's IC 50 for NMDARs at voltages near rest is ϳ1 M (Johnson and Kotermanski, 2006; Parsons et al., 2007) . Memantine has been found to exhibit only weak NMDAR subtype selectivity, with an IC 50 for NR1/2A receptors ϳ2-to several-fold higher than for NR1/2B, NR1/2C, and NR1/2D receptors (Dravid et al., 2007; Parsons et al., 2007 (Kashiwagi et al., 2002; Chen and Lipton, 2005) , and hindrance of memantine binding by Mg 2ϩ o (Sobolevsky et al., 1998) suggest that physiological Mg We compared memantine inhibition of whole-cell currents recorded at Ϫ66 mV from HEK293T cells transfected with cDNAs encoding the NR1 and either the NR2A, NR2B, NR2C, or We also investigated the effects of Mg 2ϩ o on NMDAR inhibition by ketamine, another channel blocker of broad clinical and pathological significance that exhibits kinetics and IC 50 values similar to memantine's. Ketamine is an important tool in schizophrenia research because it is psychotomimetic in healthy adults, exacerbates symptoms in schizophrenics (Krystal et al., 2003) , and is used to generate animal models of the disease (Moghaddam and Jackson, 2003) . Ketamine also is used as a pediatric and veterinary anesthetic and may be useful as a treatment for conditions including neuropathic pain (Annetta et al., 2005) . Ketamine has been reported to be largely unselective among NMDAR subtypes (Yamakura et al., 1993; Dravid et al., 2007) . However, as with memantine, nearly all studies of ketamine IC 50 and selectivity were performed in 0 Mg 2ϩ o ; when interactions have been examined, NMDAR inhibition by ketamine was reported to be both reduced (MacDonald et al., 1991) and augmented (Liu et al., 2001) by Mg o are not specific to memantine, a conclusion also supported by previous data indicating that the ketamine analog phencyclidine interacts competitively with Mg 2ϩ o when inhibiting NMDAR responses (Lerma et al., 1991) . Because of the structural dissimilarity of memantine and ketamine, the results presented here suggest that NMDAR channel-blocking drugs generally interact competitively with Mg (Rogawski and Wenk, 2003; Lipton, 2006; Parsons et al., 2007 (Fig. 3A) . Positively charged extracellular channel blockers typically inhibit less effectively with membrane voltage depolarization. In contrast, over a range of 10's of mV around resting voltage in Mg 2ϩ o , memantine inhibition of all NMDAR subtypes was predicted to moderately increase (IC 50 s to (Fig. 3B ) parallel results with memantine.
Discussion
The above results reveal that Mg (Dravid et al., 2007; Parsons et al., 2007) and the high expression of NR2A and NR2B subunits in cortex (Cull-Candy and Leszkiewicz, 2004) , research generally has focused on memantine interactions with NR2A-and/or NR2B-containing receptors (Blanpied et al., 1997; Kashiwagi et al., 2002; Chen and Lipton, 2005; Parsons et al., 2007) . Our data indicate that memantine is unlikely to act therapeutically by inhibiting NR1/2A or NR1/2B receptors: in physiological Mg 2ϩ o and at voltages near rest, the memantine IC 50 s for NR1/2A and NR1/2B receptors is over tenfold higher than therapeutic brain concentrations (Fig. 1, Table 1 ). The therapeutic utility of memantine has been hypothesized to be related to its weak selectivity for NR2C-and NR2D-containing receptors (observed in 0 Mg Table 1 ). These data suggest that NR2C-and/or NR2D-containing NMDARs are likely sites of therapeutic memantine action. In 1 mM Mg 2ϩ o , depolarizations around resting voltage were predicted to decrease moderately memantine's and ketamine's IC 50 s for all four NMDAR subtypes (Fig. 3) (data for NR1/2B and NR1/2C not shown). Measured IC 50 s at Ϫ26 mV supported the accuracy of the model ( Fig. 3; supplemental Table, available at www.jneurosci.org as supplemental material). The reversal by Mg 2ϩ o of the voltage dependence of memantine block is consistent with the hypothesis that memantine may act therapeutically by preferentially inhibiting NMDARs of depolarized neurons (Rogawski and Wenk, 2003; Lipton, 2006; Parsons et al., 2007) . The decrease of IC 50 with depolarization also might permit therapeutic memantine concentrations to mediate an appreciable inhibition of NR1/2A and NR1/2B receptors in depolarized neurons. However, the predicted minimum memantine IC 50 s for NR1/2A (4.9 M at Ϫ24 mV) and NR1/2B (3.6 M at Ϫ23 mV) receptors are well above memantine's therapeutic concentration range and are at quite depolarized voltages. Consistent with model predictions, the NR1/2A receptor IC 50 measured at Ϫ26 mV is 6.34 M (supplemental Table, available at www.jneurosci.org as supple- Memantine also inhibits other receptors with low IC 50 s, including nicotinic acetylcholine receptors (nAChRs) (Oliver et al., 2001; Maskell et al., 2003; Aracava et al., 2005; Parsons et al., 2007) . It was argued that inhibition of nAChRs is unlikely to be the basis of memantine's therapeutic utility in Alzheimer's disease (Johnson and Kotermanski, 2006; Parsons et al., 2007) because other Alzheimer's disease treatments augment cholinergic transmission. However, especially given the increased memantine IC 50 s for NMDARs reported here, a contribution to memantine's clinical utility by actions at other receptors is difficult to exclude (see below).
The clinical effects of memantine and ketamine suggest that preferential inhibition of NR2C-and/or NR2D-containing NMDARs can strongly impact cognitive function. NR2C and NR2D subunits are broadly expressed in the adult mammalian brain, including in hippocampus, cortex, and thalamus, brain regions hypothesized to be involved in Alzheimer's disease and/or schizophrenia. A possible consequence of inhibition of NR2D-containing NMDARs is preferential reduction of tonic NMDAR-mediated pyramidal cell currents, which may be carried by extrasynaptic NR1/2D receptors (Le Meur et al., 2007) . Alternatively, inhibition of NR2D-containing receptors could selectively reduce excitation of a subset of inhibitory neurons that highly express the NR2D subunit (Monyer et al., 1994 ) (see supplemental material, available at www.jneurosci.org), an effect that may contribute to the clinical utility of memantine. In Alzheimer's disease, amyloid-␤ accumulation (especially in excitatory pyramidal neurons) (D'Andrea and Nagele, 2006) can cause internalization of NMDARs (Snyder et al., 2005) and preferential loss in cortex of excitatory terminals (Bell and Claudio Cuello, 2006) . Memantine could partially counterbalance an amyloid-␤-induced reduction of cortical excitation by preferentially antagonizing NMDARs on inhibitory interneurons; if this suggestion is correct, then more selective inhibition of NR1/2D receptors may hold therapeutic promise. The clinical utility of memantine may be enhanced by its inhibition of ␣-7 nAChRs [reported memantine IC 50 ranges from 0.34 (Aracava et al., 2005) to 5 M (Maskell et al., 2003) ], receptors that participate in amyloid-␤-induced NMDAR internalization (Snyder et al., 2005) . Ketamine shows a similar (although weaker) preferential inhibition of NR1/2D and especially NR1/2C receptors (Fig. 2) that is predicted to reverse at moderately depolarized voltages (Fig. 3B) , properties that suggest more complex subtype selectivity. Ketamine's selectivity for NR1/2C and NR1/2D receptors at voltages near rest also may lead to cortical disinhibition, a process hypothesized to be responsible for ketamine's ability to induce a schizophrenia-like psychotic state (Greene, 2001; Homayoun and Moghaddam, 2007; Lisman et al., 2008) . These ideas emphasize the importance of understanding the roles played by NR2C and NR2D subunits in brain function, and the mechanisms that underlie the diverse clinical actions of NMDAR channel blockers. 
